18 results with keyword: 'inotuzumab ozogamicin pediatric patients relapsed refractory lymphoblastic leukemia'
Hepatic adverse event pro fi le of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase
N/A
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
N/A
Phase II study of the salvage mini-hyper-CVD in combination with inotuzumab ozogamicin (INO) for adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia
N/A
National Institute for Health and Care Excellence, TA 541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (19 September 2018)
N/A
Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory
N/A
In 2017, as a result of the positive Phase 3 clinical trial comparing inotuzumab ozogamicin to standard chemotherapy, the drug (under the trade name Besponsa) was approved
N/A
Nelarabine has been primarily evaluated in adult and pediatric patients diagnosed with T-cell lymphoblastic lymphoma or leukemia whose disease is refractory or has relapsed while
N/A
therapies such as chimeric antigen receptor (CAR) T cells, which have revolutionized the treat- ment of pediatric patients with relapsed or refractory B-cell acute
N/A
Gemtuzumab Ozogamicin (Mylotarg [Registered]) Expanded Access Protocol for Treatment of Patients in the United States with Relapsed/ Refractory Acute Myelogenous Leukemia Who
N/A
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following
N/A
Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following
N/A
Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia
N/A
Blinatumomab can induce molecular remission in pediatric patients with posttransplant relapsed B-precursor acute lymphoblastic leukemia and facilitate subsequent
N/A
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
N/A
For NHL clinical studies, determination of the presence of anti-rituximab antibodies followed a sequential process that included (1) screening and (2) concurrent titer de-
N/A
Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia- positive acute lymphoblastic leukemia
N/A
Current clinical trials investigating Inotuzumab in ALL include; a Phase I/II studying 2 different doses of Inotuzumab in combination with chemotherapy as frontline treatment in
N/A
Results of two major studies are awaited: a larger Phase I trial to evaluate pharmacokinetics, levels of MRD, and response is ongoing (B1931010 trial), and a Phase III pivotal
N/A